An experimental drug could be game-changing for millions of Americans with a higher genetic risk of cardiovascular disease.

This is a major source of cardiovascular morbidity and mortality. We have never been able to treat lipoprotein(a) until now.” ...

Leqembi — sold through a partnership between Eisai Co. and Cambridge-based Biogen — is one of the first medications approved ...

Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...

Drug abuse continues to grow exponentially. The U.S. alone pours billions of dollars into this never-ending war and has a ...

Dr. Peter Marks was offered the choice of resigning or being fired by Kennedy, according to a former FDA official familiar ...

A top vaccine official at the Food and Drug Administration (FDA) resigned, citing Health and Human Services (HHS) Secretary ...

Despite the president designating the group as a terrorist organization, almost all of the 37 men flagged by Chicago police ...

The US Department of Health and Human Services announced Thursday it is cutting 10,000 full-time employees across health ...

Although itolizumab did not improve response rates at Day 29 for patients with acute GVHD, the therapy showed significant ...

Health and Human Services Secretary Robert F. Kennedy Jr. is expected to announce 10,000 employees will be cut, the Wall ...

Delandistrogene moxeparvovec, a gene therapy approved for the treatment of Duchenne muscular dystrophy (DMD), was found ...